TR201721505A2 - Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon - Google Patents

Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon Download PDF

Info

Publication number
TR201721505A2
TR201721505A2 TR2017/21505A TR201721505A TR201721505A2 TR 201721505 A2 TR201721505 A2 TR 201721505A2 TR 2017/21505 A TR2017/21505 A TR 2017/21505A TR 201721505 A TR201721505 A TR 201721505A TR 201721505 A2 TR201721505 A2 TR 201721505A2
Authority
TR
Turkey
Prior art keywords
linagliptin
metformin
combination
present
composition
Prior art date
Application number
TR2017/21505A
Other languages
English (en)
Inventor
Türkyilmaz Ali̇
Pehli̇van Akalin Nur
Ergun Donmez Merve
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/21505A priority Critical patent/TR201721505A2/tr
Priority to PCT/TR2018/050857 priority patent/WO2019194773A2/en
Priority to EP18913688.0A priority patent/EP3731837A4/en
Publication of TR201721505A2 publication Critical patent/TR201721505A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, linagliptin, metformin ve en az bir farmasötik olarak kabul edilebilir eksipiyan içeren katı oral farmasötik kompozisyon ile ilgilidir. Ayrıca mevcut buluş, söz konusu kompozisyonu hazırlama yöntemi de sunmaktadır.
TR2017/21505A 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon TR201721505A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
PCT/TR2018/050857 WO2019194773A2 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin
EP18913688.0A EP3731837A4 (en) 2017-12-25 2018-12-21 COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon

Publications (1)

Publication Number Publication Date
TR201721505A2 true TR201721505A2 (tr) 2019-07-22

Family

ID=67900634

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon

Country Status (3)

Country Link
EP (1) EP3731837A4 (tr)
TR (1) TR201721505A2 (tr)
WO (1) WO2019194773A2 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (en) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
WO2023002036A1 (en) * 2021-07-22 2023-01-26 Krka, D.D., Novo Mesto Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride
WO2023075826A1 (en) * 2021-10-28 2023-05-04 The Texas A&M University System Compositions of stable metformin and similar drug products with control on nitroso impurities
WO2023163510A1 (ko) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130137624A (ko) 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
EP2848242A1 (en) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
WO2015107536A2 (en) * 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Fixed dose combination comprising linagliptin and metformin hci
WO2015110962A1 (en) * 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof

Also Published As

Publication number Publication date
WO2019194773A2 (en) 2019-10-10
WO2019194773A3 (en) 2019-12-12
EP3731837A2 (en) 2020-11-04
EP3731837A4 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
MY197700A (en) Compounds useful for inhibiting cdk7
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
MX2017016802A (es) Formulaciones farmaceuticas.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
IL285421A (en) History of indazolyl-isoxazole, their preparation and pharmaceutical preparations containing them
IL290469A (en) Oral pharmaceutical preparation
EP3750537A4 (en) PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MX2017008983A (es) Composición farmaceútica de sulfonamida.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
PH12020500120A1 (en) Pharmaceutical compositions
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
EP4071170A4 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION METHOD AND ITS USE